Literature DB >> 31741615

Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia.

Pavan Reddy1, Ramesh Shankar2, Teena Koshy3, Venkatraman Radhakrishnan1, Prasanth Ganesan1, P K Jayachandran1, Manikandan Dhanushkodi1, Nikita Mehra1, S Krupashankar1, P Manasa2, R P Nagare2, R Swaminathan4, Krishnarathinam Kannan1, T G Sagar1, T S Ganesan1.   

Abstract

Acute lymphoblastic leukemia (ALL) accounts for 20% of all adult leukemias and is the most common leukemia during childhood (80%). We present data on cytogenetics of ALL from a tertiary centre in India correlating it with clinical factors. Karyotyping of bone marrow samples of 204 patients with newly diagnosed ALL was performed with standard G-banding technique. Clinical data of patients was obtained from case records. Survival was estimated using Kaplan-Meir curves and compared by the log-rank test. Univariate and multivariate analysis was done for survival with age, sex, immunophenotype, hyperleukocytosis, risk type, remission status and cytogenetics. The most common karyotypes observed were normal in 39.7% (N = 81), hyperdiploidy in 12.7% (N = 26), t(9;22) in 4.4% (N = 9), t(1;19) in 3.9% (N = 8). Adults with ALL had worse survival compared with pediatric patients (HR 3.62; 2.03-6.45 95% CI, p < 0.001). Patients not in morphologic remission after induction chemotherapy fared poorly (HR 4.86; 2.67-8.84 95% CI, p < 0.001). Patients with favourable cytogenetics had better overall survival (HR 0.36; 0.12-1.05 95% CI, p < 0.05). On multivariate analysis, achievement of morphologic remission emerged as single most significant predictor of survival (p < 0.001). MLL gene rearrangement and t(12;21) were seen less commonly as compared to Western data. However, incidence rates of various cytogenetic abnormalities were similar to that reported from other centres from India. Age, morphologic remission at end of induction chemotherapy and favourable cytogenetics correlated significantly with survival. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Cytogenetics; India; Karyotype; Overall survival

Year:  2019        PMID: 31741615      PMCID: PMC6825071          DOI: 10.1007/s12288-019-01123-8

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  28 in total

1.  Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group.

Authors:  F M Uckun; M G Sensel; H N Sather; P S Gaynon; D C Arthur; B J Lange; P G Steinherz; P Kraft; R Hutchinson; J B Nachman; G H Reaman; N A Heerema
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

2.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

3.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.

Authors:  Anthony V Moorman; Hannah M Ensor; Sue M Richards; Lucy Chilton; Claire Schwab; Sally E Kinsey; Ajay Vora; Chris D Mitchell; Christine J Harrison
Journal:  Lancet Oncol       Date:  2010-04-19       Impact factor: 41.316

4.  Childhood acute lymphoblastic leukemia with both t(1;19) and t(9;22).

Authors:  T C Griffin; G E Tomlinson; S C Raimondi; C Sandoval; C F Timmons; C Rosenfield; A J Carroll; N R Schneider
Journal:  Leukemia       Date:  1992-06       Impact factor: 11.528

5.  Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region.

Authors:  Ching-Hon Pui; Paul S Gaynon; James M Boyett; Judith M Chessells; André Baruchel; Willem Kamps; Lewis B Silverman; Andrea Biondi; Dörthe O Harms; Etienne Vilmer; Martin Schrappe; Bruce Camitta
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

6.  A Novel Cryptic Three-Way Translocation t(2;9;18)(p23.2;p21.3;q21.33) with Deletion of Tumor Suppressor Genes in 9p21.3 and 13q14 in a T-Cell Acute Lymphoblastic Leukemia.

Authors:  Moneeb A K Othman; Martina Rincic; Joana B Melo; Isabel M Carreira; Eyad Alhourani; Friederike Hunstig; Anita Glaser; Thomas Liehr
Journal:  Leuk Res Treatment       Date:  2014-10-08

7.  Impact of cytogenetics on outcomes in pediatric acute lymphoblastic leukemia.

Authors:  Rachana Chennamaneni; Sadashivudu Gundeti; Meher Lakshmi Konatam; Stalin Bala; Ashok Kumar; Lakshmi Srinivas
Journal:  South Asian J Cancer       Date:  2018 Oct-Dec

Review 8.  Philadelphia positive acute lymphoblastic leukaemia of childhood.

Authors:  Louise K Jones; Vaskar Saha
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

9.  Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.

Authors:  Stefania Aliano; Gabriella Cirmena; Giuseppina Fugazza; Roberto Bruzzone; Claudia Palermo; Mario Sessarego
Journal:  Leuk Res Rep       Date:  2013-08-31

10.  Acute lymphoblastic leukemia: A single center experience with Berlin, Frankfurt, and Munster-95 protocol.

Authors:  Venkatraman Radhakrishnan; Sumant Gupta; Prasanth Ganesan; Rejiv Rajendranath; Trivadi S Ganesan; Kamalalayan Raghavan Rajalekshmy; Tenali Gnana Sagar
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Oct-Dec
View more
  1 in total

1.  Transcriptomic Analysis of Conserved Telomere Maintenance Component 1 (CTC1) and Its Association with Leukemia.

Authors:  Saadiya Zia; Netasha Khan; Komal Tehreem; Nazia Rehman; Rokayya Sami; Roua S Baty; Faris J Tayeb; Majed N Almashjary; Nouf H Alsubhi; Ghadeer I Alrefaei; Ramla Shahid
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.